Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged postoperative low molecular weight heparin prophylaxis after abdominal or pelvic cancer surgery
ChiCTR1800016229Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of low molecular weight heparin calcium in venous thromboembolism (VTE) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: VTE occurrence in the 4th week after operation and VTE occurrence in the 8th week after operation. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR1800016229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016229.